Journal
ANTIVIRAL RESEARCH
Volume 128, Issue -, Pages 57-62Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2016.02.005
Keywords
Lactimidomycin; Translation inhibitor; Antiviral; Dengue virus; Broad spectrum; Host-targeted antiviral
Categories
Funding
- NIH [U54AI057159, R01 AI076442]
- John and Virginia Kaneb Fellowship
Ask authors/readers for more resources
Dengue virus, a member of the Flaviviridae family, is a mosquito-borne pathogen and the causative agent of dengue fever. Despite the nearly 400 million new infections estimated annually, no vaccines or specific antiviral therapeutics are currently available. We identified lactimidomycin (LTM), a recently established inhibitor of translation elongation, as a potent inhibitor of dengue virus 2 infection in cell culture. The antiviral activity is observed at concentrations that do not affect cell viability. We show that Kunjin virus and Modoc virus, two other members of the Flavivirus genus, as well as vesicular stomatitis virus and poliovirus 1, are also sensitive to LTM. Our findings suggest that inhibition of translation elongation, an obligate step in the viral replication cycle, may provide a general antiviral strategy against fast replicating RNA viruses. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available